...
首页> 外文期刊>Clinical Hypertension >A Nationwide multicenter registry and biobank program for deep phenotyping of idiopathic and hereditary pulmonary arterial hypertension in Korea: the PAH platform for deep phenotyping in Korean subjects (PHOENIKS) cohort
【24h】

A Nationwide multicenter registry and biobank program for deep phenotyping of idiopathic and hereditary pulmonary arterial hypertension in Korea: the PAH platform for deep phenotyping in Korean subjects (PHOENIKS) cohort

机译:韩国特发性和遗传性肺动脉高压的深度多中心注册表和BioBank计划:韩国科目(Phoeniks)队列的深层表型PAH平台

获取原文
           

摘要

Pulmonary arterial hypertension (PAH) is a progressive, chronic disease without curative treatment. Large registry data of these patient populations have been published, although, phenotypic variants within each subtype of PAH have not been elucidated. As interest towards personalized medicine grows, the need for a PAH cohort with a comprehensive understanding of patient phenotypes through multiomics approaches, called deep phenotyping, is on the rise. The PAH Platform for Deep Phenotyping in Korean Subjects (PHOENIKS) cohort is designed to collect clinical data as well as biological specimens for deep phenotyping in patients with idiopathic PAH (IPAH) and heritable PAH (HPAH) in Korea. A total of 17 regional hospitals are currently working on enrolling up to 100 consecutive IPAH/HPAH patients for obtaining clinical data and biological specimens across Korea. The diagnosis of PAH is based on right heart catheterization. All clinical data is stored in a government-based online database. Each participating hospitals collect a whole blood sample from each patient, through which DNA, RNA, serum, plasma, and peripheral blood mononuclear cells will be extracted from the buffy coat layer for further multiomics analysis. Not applicable. The PHOENIKS cohort is enrolling IPAH and HPAH patients across Korea to determine the prognosis and drug response in different phenotypic variant. The data generated by this cohort are expected to open new doors for personalized medicine in PAH patients of South Korea. ClinicalTrials.gov NCT03933579. Registered on May 1st, 2019.
机译:肺动脉高压(PAH)是一种没有治疗的进步性,慢性疾病。已经公布了这些患者群体的大型注册表数据,但是PAAH的每个亚型内的表型变体尚未被阐明。随着对个性化医学的兴趣增长,通过多组合方法综合了解患者表型的PAH队列的需要,称为深度表型,正在上升。韩国科目(凤凰城)队列的PAH平台旨在收集临床数据以及韩国特发性Pah(IPAH)和遗传性PAH(HPAH)的患者的深层表型生物标本。共有17家区域医院目前正在致力于在韩国享受临床数据和生物标本的连续100名连续IPAH / HPAH患者。 PAH的诊断基于右心导管插入率。所有临床数据都存储在基于政府的在线数据库中。每个参与医院从每位患者收集整个血液样本,通过该血液样本通过该血液样本,通过该血液样本,通过该血液中的DNA,RNA,血清,血浆和外周血单核细胞将从Buffy涂层中提取,以进行进一步的多组合器分析。不适用。 Phoeniks Cohort正在韩国划分IPAH和HPAH患者,以确定不同表型变异的预后和药物反应。该队列产生的数据预计将为韩国PAH患者的个性化药物开辟新的门。 ClinicalTrials.gov NCT03933579。 2019年5月1日注册。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号